Health Catalyst (NASDAQ:HCAT – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.
Institutional and Insider Ownership
85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 2.6% of Health Catalyst shares are held by insiders. Comparatively, 33.9% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Health Catalyst and Bullfrog AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Health Catalyst | -31.67% | -7.21% | -3.28% |
| Bullfrog AI | N/A | -173.15% | -146.31% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Health Catalyst | $306.58 million | 0.67 | -$69.50 million | ($1.51) | -1.93 |
| Bullfrog AI | $60,000.00 | 215.04 | -$6.99 million | ($0.81) | -1.58 |
Bullfrog AI has lower revenue, but higher earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Health Catalyst and Bullfrog AI, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Health Catalyst | 0 | 7 | 5 | 0 | 2.42 |
| Bullfrog AI | 0 | 0 | 0 | 0 | 0.00 |
Health Catalyst currently has a consensus target price of $6.1818, indicating a potential upside of 111.71%. Given Health Catalyst’s stronger consensus rating and higher possible upside, analysts plainly believe Health Catalyst is more favorable than Bullfrog AI.
Volatility & Risk
Health Catalyst has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
Summary
Health Catalyst beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
